Since our founding in 2000, Retina Consultants of Charleston’s mission has been to provide excellence in patient care for eye disease and education of eye care providers and patients. To maintain excellence, research must be an integral part of this mission.

Physicians at Retina Consultants of Charleston were among the first to use intravitreal antiangiogenics to treat retinal diseases. Today, our Clinical Trials Division, under the direction of Dr. Monica Rodriguez-Fontal, maintains a strong commitment to medical research, which contributes to advances in Ophthalmology and related areas of medicine.

Research of medical practitioners is facilitated by a staff of ophthalmologist, neuroophthalmologists, and ophthalmic technicians, who work together to keep the Clinical Trials Division in the loop of the latest investigative trials.

Retina Consultants of Charleston continues to be involved in many clinical research projects. This site makes information about these trials available to all.

Clinical Trials Facility

Clinical Trials Staff

Clinical Trials Patients and Location

Refer a Clinical Trial Patient

Ongoing Clinical Trials:

Phase 4 Study: NO SHAM ARM
Study to Assess Best Corrected Visual Acuity (BCVA) in Patients With Neovascular Age-Related Macular Degeneration (AMD) Who Are Administered VEGF Trap-Eye (Intravitreal Aflibercept Injection) (RE-VIEW)
Clinical study looking for Rigorous Evaluation of Vision and safety after treatment with EYLEA.
Sponsor: Regeneron Pharmaceuticals
Status: Active Enrollment

Dry AMD study
Clinical Study to Investigate Safety and Efficacy of GSK933776 in Adult Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration. Active enrolling patients with Dry Age Related Macular Degeneration.
Sponsor: GlaxoSmithKline.
Status: Active Enrollment

Non-Infectious Uveitis
Study Assessing Double-Masked Uveitis Treatment (SAKURA): A Phase III, Multinational, Multicenter, Randomized, Double-Masked, Study Assessing the Safety and Efficacy of Intravitreal Injections of DE-109 (three doses) for the treatment of active, Non-Infectious Uveitis of the Posterior Segment of the eye.
Sponsor: Santen Inc.
Status: Active Enrollment

Retina Vein Occlusion and Macular Edema
VIBRANT study: Study to Assess the Clinical Efficacy and Safety of VEGF Trap-Eye (Intravitreal Aflibercept Injection [IAI]), Also Commercially Known as EYLEA™ in Patients With Branch Retinal Vein Occlusion (BRVO)
Sponsor: REGENERON
Status: Active, enrollment complete

Closed Clinical Trials:

Retina Vein Occlusion and Macular Edema
SHORE Study FVF4967g:
A Multi-Center Randomized Study Evaluating Dosing Regimens For Treatment With Intravitreal Ranibizumab Injections in Subjects With Macular Edema Following Retinal Vein Occlusion. Patients will receive Ranibizumab injections for 7 months then they will be randomized to either PRN or Fixed group depending on retina status.
Sponsor: Genentech
Status: Closed

Age Related Macular Degeneration
HARBOR Study FVF4579g: A Phase III, Double-Masked, Multicenter, Randomized, Active Treatment–Controlled Study Of The Efficacy And Safety Of 0.5 Mg And 2.0 Mg Ranibizumab Administered Monthly Or On An As Needed Basis (PRN) In Patients With Subfoveal Neovascular Age-Related Macular Degeneration.
Sponsor: GENENTECH
Status: Closed

HORIZON Study FVF 3426g: An Open-Label, Multicenter Extension Study To Evaluate The Safety And Tolerability Of Ranibizumab In Subjects With Choroidal Neovascularization (CNV) Secondary To Age Related Macular Degeneration (AMD) Or Macular Edema Secondary To Retinal Vein Occlusion (RVO) Who Have Completed A Genentech Sponsored Ranibizumab Study.
Sponsor: GENENTECH
Status: Closed

Diabetic Macular Edema
RISE Study FVF 4170g: A Phase III, Double-Masked, Multicenter, Randomized, Sham Injection-Controlled Study Of The Efficacy And Safety Of Ranibizumab Injection In Subjects With Clinically Significant Macular Edema With Center Involvement Secondary To Diabetes Mellitus.
Sponsor: GENENTECH
Status: Closed

MARINA FVF2598g: A Phase III, Multicenter, Randomized, Double-Masked, Sham Injection Controlled Study of the Efficacy and Safety of rhuFab V2 (Ranibizumab) in Subjects with Minimally Classic or Occult Subfoveal Neovascular Age-Related Macular Degeneration.
ANCHOR: A Phase III, Multicenter, Randomized, Double-Masked, Sham Injection Controlled Study of the Efficacy and Safety of rhuFab V2 (Ranibizumab) in Subjects with Classic Neovascular Age-Related Macular Degeneration.
SAILOR FVF3689g: A Phase IIIb, Single-Masked, Multicenter, Randomized Study to Evaluate the Safety and Tolerability of Ranibizumab in Naïve and Previously Treated Subjects with Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration
FAME C 01-05-001: Fluocinolone Acetonide in Diabetic Macular Edema.
CRUISE FVF416g: A Study of the Efficacy and Safety of Ranibizumab Injection in Patients With Macular Edema Secondary to Central Retinal Vein Occlusion.
BRAVO FVF4165g: A Study of the Efficacy and Safety of Ranibizumab Injection in Patients With Macular Edema Secondary to Branch Retinal Vein Occlusion.
SCORE: The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study: Two Randomized Trials to Compare the Efficacy and Safety of Intravitreal Injection(s) of Triamcinolone Acetonide With Standard Care to Treat Macular Edema.
LION: Lucentis for Ischemic Optic Neuropathy.